10x Genomics (TXG) Change in Accured Expenses (2018 - 2026)

10x Genomics has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$6.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$6.1 million, down 241.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.6 million (down 466.02% YoY), and the FY2025 annual result was -$5.2 million, up 59.54% from the prior year.
• Change in Accured Expenses came in at -$6.1 million for Q1 2026 at 10x Genomics, down from $4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.6 million in Q2 2023 to a low of -$15.1 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $547000.0 (2024), against an average of -$1.4 million.
• Across the five-year window, Change in Accured Expenses jumped 1091.03% in 2022 and plunged 1419.93% in 2025, its largest moves.
• 10x Genomics' Change in Accured Expenses stood at $6.5 million in 2022, then tumbled by 281.41% to -$11.8 million in 2023, then surged by 137.31% to $4.4 million in 2024, then climbed by 8.8% to $4.8 million in 2025, then sank by 228.21% to -$6.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.1 million (Q1 2026), $4.8 million (Q4 2025), and -$7.0 million (Q3 2025), per Business Quant data.